Sustainable anticoagulation for climate resilient care.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 40972616.
- Also identified by DOI 10.1016/S2352-3026(25)00204-2.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This Viewpoint issues a multidisciplinary call to embed sustainability into anticoagulation care, aligning clinical excellence with climate responsibility. Anticoagulation management-including drug manufacturing, laboratory diagnostics, therapeutic monitoring, and long-term follow-up-contributes substantially to health-care-associated carbon emissions. We propose a systems-level decarbonisation strategy, anchored in life cycle assessment methodology, to quantify emissions across anticoagulation care and identify high-impact intervention points. Core strategies include reducing unnecessary laboratory testing, greening laboratory operations through recyclable consumables and energy-efficient infrastructure, transitioning to lower-carbon anticoagulants, and promoting antithrombotic stewardship to reduce dosing errors and drug waste. Digital health technologies, such as telemedicine, artificial intelligence, and mobile apps, are positioned as enablers of low-emission, patient-centred care. Circular economy principles and carbon-informed procurement are integrated into the therapeutic pathway, supported by policy levers that incentivise sustainable practices. Finally, we call for inclusive engagement of low-income and middle-income country stakeholders to ensure equitable, scalable, and context-appropriate implementation of climate-resilient thrombosis care.
Medical subject headings
- Anticoagulants
- Climate Change
- Hematology
- Sustainable Development